Clinical Trial

PET/CT Imaging in Carriers of TTR Mutations

Study acronym: EPIC-TTR
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this study is to determine if TTR gene carriers have early signs of a type of heart disease called amyloidosis using a new radiotracer dye (iodine-124 evuzamitide, I-124E). Participants will undergo a screening that includes a medical history review and completion of quality-of-life surveys. Once screening is complete, participants will undergo an imaging test called a positron emission tomography (PET) scan combined with computed tomography (PET/CT) to make images of the body. The new radiotracer dye (I-124E, a radioactive contrast) will be used during the PET/CT to make amyloidosis visible in the heart and body.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-05-08.
Trial Details
NCT Number NCT07591038
Lead Sponsor University of Texas Southwestern Medical Center
Collaborators: National Heart, Lung, and Blood Institute (NHLBI), Bayer
Conditions ATTR, ATTR Gene Mutation, Cardiomyopathy, Transthyretin Mediated Amyloidosis (ATTR)
Enrollment 80 participants
Start Date 2026-08-01
Primary Completion 2030-06-30 (estimated)
Study Completion 2030-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-19